Piper Sandler Maintains Overweight on Allogene Therapeutics, Raises Price Target to $8

Benzinga Newsdesk www.benzinga.com Positive 81.1%

Neg 0% Neu 0% Pos 81.1%

Piper Sandler analyst Biren Amin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Overweight and raises the price target from $7 to $8.